Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Condition: Solid Tumors
MeSH terms: Neoplasms
Intervention: PLX3397; Paclitaxel
Intervention description: PLX3397 tablets, 200mg; Paclitaxel IV
Intervention MeSH terms: Paclitaxel
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 74.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: advanced, incurable solid tumors

Summary:

      This was a 3-part study designed to explore the safety and tolerability of escalating doses
      of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm
      RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy
      of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in
      participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory
      epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients with:

               -  Part 1 (enrollment closed): an advanced, incurable solid tumor

               -  Part 2 (enrollment closed): an advanced, incurable solid tumor for whom a taxane
                  would be considered a reasonable chemotherapy option

               -  Part 3 (enrollment closed): advanced, metastatic or non-resectable epithelial
                  ovarian cancer, primary peritoneal cancer or fallopian tube cancer with

                    -  platinum-resistant cancer, defined as disease that responded to a
                       platinum-containing chemotherapy regimen, but demonstrated recurrence within
                       six months following the completion of that platinum-containing regimen, OR

                    -  platinum-refractory cancer, defined as disease failed to achieve at least a
                       partial response to a platinum-containing regimen (i.e., stable disease or
                       actual disease progression), AND

                    -  have not been treated with a taxane within six months of Cycle 1 Day 1
                       (C1D1), AND

                    -  have not been treated with weekly paclitaxel after first-line treatment in
                       which weekly paclitaxel plus a platinum is permitted

          -  Part 3: Patients must have target (≥2 cm diameter) or non-target lesion cancer that is
             accessible for core biopsies before starting on study and after one cycle of
             treatment.

          -  Patients with stable brain metastases are eligible for this trial. However, patients
             must not have required steroid treatment for their brain metastases within 30 days of
             Screening.

          -  Bone-directed therapy (e.g., bisphosphonates or denosumab) is permitted.

          -  Washout from any prior investigational therapy of at least five times the T1/2 prior
             to C1D1

          -  Washout from any prior biologic or targeted therapy at least 4 weeks or five times the
             plasma half-life (T1/2) (whichever is shorter) prior to C1D1

          -  Washout from prior chemotherapy of at least 2 weeks or 1 elimination half-life,
             whichever is longer, prior to C1D1

          -  Washout from prior hormonal therapy of at least 2 weeks prior to C1D1

          -  Washout of at least 2 weeks from the most recent radiation treatment prior to C1D1

          -  Resolution of all prior treatment-related toxicities to Grade 1 or less, except for
             Grade 2 fatigue or alopecia prior to C1D1

          -  Age eighteen years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2, inclusive

          -  Anticipated life expectancy of at least 12 weeks

          -  Adequate bone marrow reserve: absolute neutrophil count (ANC) ≥1500/mm3, platelets
             ≥100,000/mm3

          -  Adequate renal function: serum creatinine <1.5 x ULN or calculated creatinine
             clearance (CrCl) >60 mL/min using Cockcroft-Gault formula

          -  Adequate hepatic function: aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) <2.5 x upper limit of normal (ULN), Total and Direct Bilirubin
             <1.5 x ULN. However, in the presence of liver metastases, AST and ALT must be <5 x ULN

          -  Cardiac ejection fraction ≥50%, and QT interval corrected by Fridericia's formula
             (QTcF) <450 ms (males) or <470 ms (females) on electrocardiogram (ECG) at Baseline.

          -  Able to swallow capsules and maintain adequate hydration

          -  Ability to give written informed consent and willing to comply with the requirements
             of the protocol; and for Part 3, to give written informed consent for 2 cancer biopsy
             procedures

          -  Women of child-bearing potential must agree to use an effective method of birth
             control during treatment and for three months after receiving their last dose of study
             drug. Fertile men must also agree to use an acceptable method of birth control while
             on study drug and for at least 3 months after last dose.

        Exclusion Criteria:

          -  Presence of an active secondary malignancy.

               -  Patients with a non-melanomatous, in situ malignancy or disease that is
                  completely resectable with surgery may be considered after discussion with the
                  Medical Monitor

               -  Patients with a completely treated prior malignancy with no evidence of disease
                  for ≥3 years are eligible

          -  Refractory nausea and vomiting, malabsorption, external biliary shunt or significant
             small bowel resection that would preclude adequate absorption of PLX3397

          -  Ongoing treatment with any other investigational therapy

          -  Prior anaphylactic or severe hypersensitivity reaction to paclitaxel or
             Cremophor-containing agent.

          -  Persistent grade 2 fatigue at Baseline.

          -  Severe, concurrent illness including congestive heart failure, significant cardiac
             disease and uncontrolled hypertension, that would likely prevent the patient from
             being able to comply with the study protocol

          -  Active untreated infection

          -  Known chronic active Hepatitis B or C, or HIV infection

          -  The presence of a medical or psychiatric condition that, in the opinion of the
             Principal Investigator, makes the patient inappropriate for inclusion in this study.